Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals Inc (NQ: PIRS )

16.83 -0.24 (-1.41%)
Streaming Delayed Price Updated: 10:52 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Via ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
Via ACCESSWIRE
Recap: Pieris Pharmaceuticals Q3 Earnings
Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate
Via Benzinga
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
Via ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers DICE Therapeutics (NASDAQ:DICE) stock moved upwards by 83.4% to $45.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.7 billion. 
Via Benzinga
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Recap: Pieris Pharmaceuticals Q1 Earnings
Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
Via ACCESSWIRE
Pieris Pharmaceuticals's Return On Capital Employed Insights
Benzinga Pro data, Pieris Pharmaceuticals (NASDAQ:PIRS) reported Q2 sales of $3.70 million. Earnings fell to a loss of $10.34 million, resulting in a 102.67% decrease from last quarter. 
Via Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
Via Benzinga
Pieris Pharmaceuticals: Q2 Earnings Insights
  Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pieris Pharmaceuticals's Earnings Outlook
Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
Via ACCESSWIRE
Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q1, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $10.99 million. Earnings were up 46.49%, but Pieris Pharmaceuticals still reported an overall loss of... 
Via Benzinga
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
4 Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded slightly lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals's Earnings Outlook
Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.